针对高脂血症的新型药物治疗方法
Brian V Reamy1, Brian Ford2, Charles Goodman2
1Academic Affairs, Uniformed Services University School of Medicine, 4301 Jones Bridge Road, Bethesda, MD 20814, USA.
Primary care
|January 26, 2024
概括
本综述涵盖了超脂血症的标准,新和新兴治疗方法,重点关注管理胆固醇和甘油三,以预防心血管疾病.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 预防医学 预防医学
背景情况:
- 脱脂症 (高LDL-C,低HDL-C,高甘油三) 和心血管疾病 (CVD) 风险之间确立的联系.
- 几十年来,许多药物已被开发和测试用于治疗脱脂症.
- 许多已建立的治疗方法在降低心血管疾病发病率和死亡率方面的有效性是明确的.
研究的目的:
- 审查目前的超脂血症标准治疗方法.
- 讨论最近批准的,以及治疗失脂症的新疗法.
- 通过管理失脂症来探索新兴治疗方法,用于通过管理失脂症来预防心血管疾病的初级和二级预防.
主要方法:
- 临床试验和药理学研究的文献综述.
- 对降脂剂的疗效和安全性数据的分析.
- 综合有关已确定的,新的和研究中的治疗方法的信息.
主要成果:
- 标准疗法有效地管理脂质不良症并降低心血管疾病风险.
- 新的药物提供了更好的疗效和耐受性.
- 新兴的治疗方法显示了通过先进的脂质管理来增强心血管疾病预防的希望.
结论:
- 对心血管健康至关重要的是全面管理失脂症.
- 有一系列的治疗选择,从标准到新型和新兴药物.
- 持续的研究和开发对于优化心血管疾病预防策略至关重要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515
Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Glucagon-like Receptor Agonists
323
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323


